Literature DB >> 17668563

The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Elena Losina1, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Bingxia Wang, Lindsey L Wolf, Eugène Messou, Delphine Gabillard, Catherine Seyler, Kenneth A Freedberg, Xavier Anglaret.   

Abstract

BACKGROUND: Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count.
OBJECTIVE: To estimate the independent impact of HAART on reducing ODs and mortality in Côte d'Ivoire.
METHODS: Within two longitudinal studies of HIV-infected adults (1996-2003), we identified time on 'cotrimoxazole alone' and 'HAART plus cotrimoxazole' WHO stage 3-4 defining events and severe malaria were divided into those preventable and not preventable with cotrimoxazole. Incidence of ODs by CD4 count stratum was estimated using incidence density analysis. CD4+ T-cell count at time of OD was estimated using linear interpolation. Using Poisson regression, we estimated the effect of HAART on OD incidence and mortality by CD4 count stratum.
RESULTS: Totals of 446 and 135 adults were followed during 6,216 and 3,412 person-months in the cotrimoxazole alone and HAART plus cotrimoxazole periods, respectively. There was a CD4+ T-cell-independent risk reduction for ODs and mortality during the HAART plus cotrimoxazole period compared with cotrimoxazole alone, which varied by time on HAART, CD4 count stratum and OD type. It was mainly seen after 6 months on HAART and for ODs not preventable by cotrimoxazole. The HAART effect differed significantly by CD4 count stratum (P=0.02), but was significant in all strata after 6 months on HAART.
CONCLUSIONS: In these sub-Saharan African adults, HAART initiation reduced ODs and mortality beyond that which was expected through the HAART-induced CD4+ T-cell increase. Further studies should examine practical implications of this independent 'HAART effect' on clinical outcomes in patients on HAART.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668563      PMCID: PMC3073611     

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  34 in total

1.  HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group.

Authors:  J L Jones; D L Hanson; M S Dworkin; K M DeCock
Journal:  Int J Tuberc Lung Dis       Date:  2000-11       Impact factor: 2.373

2.  Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi.

Authors:  Rony Zachariah; Margaret Fitzgerald; Moses Massaquoi; Olesu Pasulani; Line Arnould; Simon Makombe; Anthony D Harries
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

3.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

4.  Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.

Authors:  E Girardi; F Palmieri; A Cingolani; A Ammassari; N Petrosillo; L Gillini; D Zinzi; A De Luca; A Antinori; G Ippolito
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-01       Impact factor: 3.731

5.  Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.

Authors:  M S Dworkin; J W Ward; D L Hanson; J L Jones; J E Kaplan
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

6.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Authors:  Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

7.  The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Authors:  V Miller; C A Sabin; A N Phillips; C Rottmann; H Rabenau; E Weidmann; V Rickerts; S Findhammer; E B Helm; S Staszewski
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

8.  Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

Authors:  Elizabeth L Corbett; Gavin J Churchyard; Salome Charalambos; Badara Samb; Vicky Moloi; Tim C Clayton; Alison D Grant; Jill Murray; Richard J Hayes; Kevin M De Cock
Journal:  Clin Infect Dis       Date:  2002-04-05       Impact factor: 9.079

9.  Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.

Authors:  J S Currier; P Williams; J Feinberg; S Becker; S Owens; C Fichtenbaum; C Benson
Journal:  Clin Infect Dis       Date:  2001-04-30       Impact factor: 9.079

10.  Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection.

Authors:  A Gregory DiRienzo; Charles van Der Horst; Dianne M Finkelstein; Peter Frame; Samuel A Bozzette; Karen T Tashima
Journal:  AIDS Res Hum Retroviruses       Date:  2002-01-20       Impact factor: 2.205

View more
  35 in total

1.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

2.  Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.

Authors:  Sarah B Lorenzana; Michael D Hughes; Beatriz Grinsztejn; Ann C Collier; Paula Mendes Luz; Kenneth A Freedberg; Robin Wood; Julie H Levison; Peter N Mugyenyi; Robert Salata; Carole L Wallis; Milton C Weinstein; Robert T Schooley; Rochelle P Walensky
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

3.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

4.  Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti.

Authors:  April D Kimmel; Macarthur Charles; Marie-Marcelle Deschamps; Patrice Severe; Alison M Edwards; Warren D Johnson; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

5.  Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

Authors:  Hans-Jürgen Stellbrink
Journal:  Core Evid       Date:  2010-06-15

6.  When to start antiretroviral therapy in resource-limited settings.

Authors:  Rochelle P Walensky; Lindsey L Wolf; Robin Wood; Mariam O Fofana; Kenneth A Freedberg; Neil A Martinson; A David Paltiel; Xavier Anglaret; Milton C Weinstein; Elena Losina
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

7.  Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.

Authors:  Rochelle P Walensky; Robin Wood; Milton C Weinstein; Neil A Martinson; Elena Losina; Mariam O Fofana; Sue J Goldie; Nomita Divi; Yazdan Yazdanpanah; Bingxia Wang; A David Paltiel; Kenneth A Freedberg
Journal:  J Infect Dis       Date:  2008-05-01       Impact factor: 5.226

8.  Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.

Authors:  Eric N Ouattara; Marion Robine; Serge P Eholié; Rachel L MacLean; Raoul Moh; Elena Losina; Delphine Gabillard; A David Paltiel; Christine Danel; Rochelle P Walensky; Xavier Anglaret; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2016-03-01       Impact factor: 9.079

9.  Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency.

Authors:  Jordan A Francke; Martina Penazzato; Taige Hou; Elaine J Abrams; Rachel L MacLean; Landon Myer; Rochelle P Walensky; Valériane Leroy; Milton C Weinstein; Robert A Parker; Kenneth A Freedberg; Andrea Ciaranello
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

10.  Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

Authors:  Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.